Advertisement
ALLR vs BCTX
Which Stock Would AI Choose? Allarity Therapeutics (ALLR) vs. BriaCell Therapeutics (BCTX) Stock Comparison
Key Takeaways
- Allarity Therapeutics (ALLR) is a clinical-stage precision oncology firm advancing stenoparib with its proprietary Drug Response Predictor (DRP) companion diagnostics, while BriaCell Therapeutics (BCTX) is a clinical-stage immuno-oncology company led by its Phase 3 Bria-IMT program for metastatic breast cancer.
- BCTX carries a larger market capitalization, a more advanced late-stage pipeline, and a heavier recent flow of positive catalysts, including conference data and a 2026 industry award.
- ALLR trades near the lower end of its 52-week range with a smaller market cap and higher financing-related risk, despite a recent Buy rating and elevated analyst price target.
- Tickeron AI Verdict: Based on observable momentum, catalyst flow, and relative market positioning, Tickeron's AI currently favors BCTX as the stronger of the two.
- For deeper context, explore ALLR Major News and ALLR Today's Price Move, plus BCTX Major News and BCTX Today's Price Move.
- To see how automated strategies are positioning across the market, explore the curated Trending AI Robots.
Introduction
This stock comparison examines two clinical-stage biotechnology companies operating at the smaller end of the market-capitalization spectrum: ALLR (Allarity Therapeutics) and BCTX (BriaCell Therapeutics). Both develop novel cancer therapies, yet they differ markedly in approach, pipeline maturity, and recent market positioning. Traders and investors focused on speculative biotech names, catalyst-driven price moves, and relative performance will find this comparison useful. Because both stocks are pre-revenue or near pre-revenue and highly sensitive to clinical and regulatory news, understanding their contrasting profiles can help frame how momentum and risk are currently distributed between them.
ALLR Overview and Recent Performance
ALLR, Allarity Therapeutics, is a precision-medicine company developing stenoparib, a dual PARP and WNT pathway inhibitor, for advanced ovarian cancer. A defining feature of its strategy is the Drug Response Predictor (DRP), a companion diagnostic approach intended to identify patients most likely to respond. In recent weeks, the company secured its first revenue-generating commercial agreement under a newly established CLIA-certified laboratory services strategy and reported advances in its DRP technology and patent portfolio, including a Japanese patent for a stenoparib companion diagnostic. On the analyst side, Ascendiant Capital maintained a Buy rating and raised its price target. Despite these developments, the shares have traded with softness in recent market activity, hovering near the lower portion of their 52-week range, with a modest market capitalization and elevated debt relative to equity adding to the risk profile.
BCTX Overview and Recent Performance
BCTX, BriaCell Therapeutics, is an immuno-oncology company developing off-the-shelf cell-based immunotherapies. Its lead candidate, Bria-IMT, is being studied in a pivotal Phase 3 trial for metastatic breast cancer, and the company is advancing a personalized platform, Bria-OTS+, across additional indications. Recent weeks have brought a steady stream of positive updates, including preclinical data presented at the SITC 2026 meeting, an ESMO 2026 biomarker poster, a Data Safety Monitoring Board recommendation to continue its Phase 3 study, expansion of the trial to Memorial Sloan Kettering Cancer Center, and a 2026 "Immunotherapy Solution of the Year" award. This catalyst flow has coincided with sharp short-term price gains, though the shares remain below their 52-week highs and continue to exhibit above-average volatility relative to the broader market.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies from a much larger universe. Tickeron offers hundreds of AI trading bots that monitor thousands of different tickers, but only the strategies best suited to current market conditions are featured in this section. These robots vary widely in trading style, strategy, timeframe, performance history, and the specific sets of tickers they trade, giving investors a range of approaches to consider. The section is designed to help users identify AI-driven signals that align with the prevailing market environment. Exploring the Trending AI Robots page can provide additional perspective on how automated systems are currently positioning across the market.
Head-to-Head Comparison
The clearest contrast between ALLR and BCTX lies in pipeline maturity and business model. ALLR pairs a drug candidate with a diagnostic platform, positioning itself as a precision-medicine play whose value depends heavily on validating the DRP approach alongside clinical outcomes. Its lead program remains in Phase 2, and the company has recently emphasized building recurring laboratory-services revenue to diversify beyond drug development. BCTX, by contrast, is further along in the regulatory pathway, with a Phase 3 pivotal study already underway and a broader platform spanning multiple cancer types.
From a market-capitalization and stability standpoint, BCTX holds a larger capitalization and a more diversified pipeline, but it also displays a higher beta (a measure of volatility relative to the market), reflecting sharp swings around news events. ALLR trades at a lower absolute price and smaller capitalization, with financing and capital-structure considerations presenting a distinct risk layer. In terms of sector exposure, both are squarely in biotechnology, but ALLR leans toward diagnostics-enabled drug development while BCTX sits in the immunotherapy segment. Recent momentum has favored BCTX, which has been supported by a consistent cadence of positive clinical and recognition-based announcements, whereas ALLR has faced more muted price action despite its own operational progress.
Tickeron AI Verdict
Weighing observable factors rather than making predictions, Tickeron's AI would likely favor BCTX in the current environment. Its relative advantages include a more advanced, late-stage clinical program, a broader pipeline, a larger market capitalization, and a steadier stream of recent positive catalysts, all of which contribute to relatively stronger trend consistency and market positioning. ALLR retains meaningful potential given its diagnostic differentiation and analyst support, but its smaller scale, earlier-stage lead asset, and capital-structure considerations present comparatively higher uncertainty. This assessment reflects probabilistic positioning based on current data and is not intended as individualized guidance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLR is a Hold and BCTX is a Hold.
ALLR's RSI Indicator leaves overbought zone
The 10-day RSI Indicator for ALLR moved out of overbought territory on November 04, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 14 instances where the indicator moved out of the overbought zone. In 14 of the 14 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 27 of 31 cases where ALLR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.
ALLR moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for ALLR moved below the 200-day moving average on October 12, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALLR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ALLR broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALLR entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on ALLR as a result. In 53 of 67 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for ALLR just turned positive on October 21, 2026. Looking at past instances where ALLR's MACD turned positive, the stock continued to rise in 29 of 31 cases over the following month. The odds of a continued upward trend are 90%.
Following a +29.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLR advanced for three days, in 144 of 176 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.361) is normal, around the industry mean (3.498). P/E Ratio (-1.227) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (52.632) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. ALLR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
BCTX's Indicator enters downward trend
The Aroon Indicator for BCTX entered a downward trend on November 09, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 235 similar instances where the Aroon Indicator formed such a pattern. In 210 of the 235 cases the stock moved lower. This puts the odds of a downward move at 89%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for BCTX crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
BCTX broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BCTX's RSI Oscillator exited the oversold zone, 37 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 62 cases where BCTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on BCTX as a result. In 74 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for BCTX just turned positive on November 06, 2026. Looking at past instances where BCTX's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
BCTX moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +23.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where BCTX advanced for three days, in 204 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.428) is normal, around the industry mean (3.498). P/E Ratio (-4.702) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. BCTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
BCTX | ||
|---|---|---|
OUTLOOK RATING 1..100 | 17 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 23 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 99 | |
PRICE GROWTH RATING 1..100 | 60 | |
P/E GROWTH RATING 1..100 | 57 | |
SEASONALITY SCORE 1..100 | 28 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ALLR | BCTX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 84% |
| Stochastic ODDS (%) | 1 day ago 87% | 1 day ago 73% |
| Momentum ODDS (%) | 1 day ago 79% | 1 day ago 78% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 83% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 87% |
| Advances ODDS (%) | 7 days ago 82% | 4 days ago 79% |
| Declines ODDS (%) | 5 days ago 90% | 11 days ago 86% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 87% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALLR’s FA Score shows that 0 FA rating(s) are green while BCTX’s FA Score has 1 green FA rating(s).
- ALLR’s FA Score: 0 green, 5 red.
- BCTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALLR’s TA Score shows that 3 TA indicator(s) are bullish while BCTX’s TA Score has 6 bullish TA indicator(s).
- ALLR’s TA Score: 3 bullish, 7 bearish.
- BCTX’s TA Score: 6 bullish, 4 bearish.
Price Growth
ALLR (@Biotechnology) experienced а +11.34% price change this week, while BCTX (@Biotechnology) price change was +29.51% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.97%. For the same industry, the average monthly price growth was -8.33%, and the average quarterly price growth was +85.08%.
Reported Earning Dates
ALLR is expected to report earnings on Nov 13, 2026.
BCTX is expected to report earnings on Dec 10, 2026.
Industries' Descriptions
@Biotechnology (+2.97% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ALLR and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALLR has been closely correlated with TAOX. These tickers have moved in lockstep 87% of the time. This A.I.-generated data suggests there is a high statistical probability that if ALLR jumps, then TAOX could also see price increases.
| Ticker / NAME | Correlation To ALLR | 1D Price Change % | ||
|---|---|---|---|---|
| ALLR | 100% | -2.68% | ||
| TAOX - ALLR | 87% Closely correlated | +7.09% | ||
| NRXP - ALLR | 81% Closely correlated | N/A | ||
| ACRV - ALLR | 48% Loosely correlated | -1.86% | ||
| BCTX - ALLR | 35% Loosely correlated | -5.57% | ||
| IVVD - ALLR | 34% Loosely correlated | +5.90% | ||
More | ||||
BCTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BCTX has been loosely correlated with CANF. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if BCTX jumps, then CANF could also see price increases.
| Ticker / NAME | Correlation To BCTX | 1D Price Change % | ||
|---|---|---|---|---|
| BCTX | 100% | -5.57% | ||
| CANF - BCTX | 59% Loosely correlated | +3.70% | ||
| ENVB - BCTX | 50% Loosely correlated | N/A | ||
| TECX - BCTX | 47% Loosely correlated | +6.06% | ||
| ALLR - BCTX | 44% Loosely correlated | -2.68% | ||
| TAOX - BCTX | 35% Loosely correlated | +7.09% | ||
More | ||||